Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    

| More

UPL - Synergy benefits on track - ICICI Securities

Posted On: 2020-08-03 08:44:46

Highlights from UPL's Q1FY21: (1) India business reported strong 27% revenue growth due to early monsoon, 14% higher sowing and market share gains, (2) Change in revenue mix, lower input prices and synergy benefits helped EBITDA margin expand 510bps YoY, (3) The synergy benefits are as per the plan and the net working capital days reduced to 84 in Q1FY21 from 115 in Q1FY20. We expect steady improvement in return ratios due to (1) synergy benefits and higher margins and (2) reduction in net working capital days. We expect earnings CAGR of 19.8% over FY20-22 with RoIC > Cost of equity. Maintain BUY with a DCF-based target price of Rs555 (12x FY22E; Earlier TP-Rs466).

- India reported strong growth: The company reported revenue decline of 0.9% in Q1FY21. (0% volume growth, -0.9% price decline and no forex impact). Revenue growth in key regions - Latin America (16%), North America (14%), India 27%, Rest of World 10% and Europe 1%. The company has maintained its long term revenue growth ambition of 7-10% per annum.

- India business reported strong growth: Due to strong agri season, 14% increase in sowing and early monsoon India business reported 27% revenue growth. Considering market growth of 15%, the company has gained market share during the quarter. The branded products portfolio grew 36% YoY.

- EBITDA margin expansion led by lower RM cost and synergy benefits: Gross margin expanded 790bps led by (1) lower input prices and (2) improvement in revenue mix. Lower revenues of Latin America (low margin region) resulted in better margins at consolidated level. Synergy benefits helped EBITDA margin expand 510bps YoY. Due to higher effective taxes, net profit grew 4.8% YoY.

- Synergy benefits on track as per plan: The cost synergy benefits worth US$109mn were achieved in FY20 and additional US$11mn benefits were achieved in Q1FY21. Revenue synergy benefits worth US$240mn were achieved in FY20 and additional US$7mn benefits were achieved in Q1FY21. We note the company is on track to achieve the stated synergy benefits in FY21-22.

- Expect improvement in return ratios: UPL is working on three broad strategies to improve return ratios as (1) improve revenues via market share gains, (2) improve margins via synergy benefits and lower input prices and (3) reduce the working capital days. The working capital days have corrected to 84 at end of Q1FY21 from 115 in Q1FY20. We expect RoE to move to 14.7% in FY22 from 8.7% in FY20.

- Maintain BUY: We model UPL to report revenue and PAT CAGRs of 10.2% and 19.8% respectively, over FY20-FY22E. We remain confident of value creation with RoIC > Cost of Equity and hence, maintain BUY rating with DCF based target price of 555 (12x FY22E).

Shares of UPL Limited was last trading in BSE at Rs.452.2 as compared to the previous close of Rs. 478.25. The total number of shares traded during the day was 622788 in over 17409 trades.

The stock hit an intraday high of Rs. 484.25 and intraday low of 445.55. The net turnover during the day was Rs. 284173119.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:


Mutual Fund Review - September, 2020 - ICICI Securities

UTI AMC announces IPO date - Angel Broking

Asian Paints - Mr. Amarjeet Maurya - AVP - Mid Caps, Angel Broking Ltd

Britannia Industries - Mr. Amarjeet Maurya - AVP - Mid Caps, Angel Broking Ltd

Hexaware Technologies (Not Rated): Hexaware accepts 475/share as final delisting price - ICICI Securities

CAMS IPO - Day 2 Subscription - Angel Boking

Chemcon Speciality Chemicals - IPO subscribed 12.62 times on second day - Angel Broking

General insurance - Fire, health remain growth drivers, rising Covid claims a concern - ICICI Securities

Supreme Industries - Perfect recipe for rerating; upgrade to BUY - ICICI Securities

Titan Company - Best positioned to gain from faster-than-expected recovery. Upgrade to ADD - ICICI Securities

Sector Update - Telecom - Sep 23, 2020 - ICICI Securities

Allcargo Logistics - Highlights of Blackstone deal - ICICI Securities

I-direct Instinct - Gokaldas Exports

Economy: RBI's trilemma: allows for INR strength - Kotak

HCL Technologies - Company Update - ICICI Securities

Chemcon Speciality Chemicals - IPO Review - ICICI Securities

Angel Broking - IPO Note - YES Securities

TCS - Announcement of its blockhchain based solutions on Microsoft Azure - Angel Broking

Amber Enterpirses acquire Sidwal - Angel Broking

Dixon Technologies - Buy - YES Securities

HCL Technologies acquisition of DWS Limited - Angel Broking

Allcargo Logistics CFO Resignation - Angel Broking

Upgrade to BUY on Gateway Distriparks - Strengthening the balance sheet - HDFC Securities

BUY on ITD Cementation - Execution pickup awaited - HDFC Securities

Allcargo Logistics - Trying to stich through an integrated offering - ICICI Securities

Polymer price tracker - Other polymer (ex-PVC) prices too firm up - ICICI Securities

Angel Broking - IPO Review - ICICI Securities

IPO Review - Computer Age Management Services - ICICI Securities

Company Update - EIH Ltd - ICICI Securities

Gladiator Stocks - Godrej Properties - ICICI Securities

Company Update - Dr Reddy's Laboratories - ICICI Securities

Gladiator Stocks: Pharma Thematic - ICICI Securities

Company Update - Housing & Urban Development - ICICI Securities

Covid Recovery Pulse - E-Way bill generation shows recovery signs with auto volumes flat - ICICI Securities

Quant Pick - UltraTech Cement - ICICI Securities

Lupin & Cipla - Positive News - Angel Broking

Sterling and Wilson Solar Ltd - 106.71 MW order win - Angel Broking

Dr. Reddy's Laboratories - Settles Revlimid litigation in US - ICICI Securities

Natco Pharma - Natco to launch first generic Revlimid - ICICI Securities

Solar Industries - Overseas and defence key to profitability - ICICI Securities

Federal Bank - Strengthening liability muscle; fees & charges revised upwards - ICICI Securities

HCL Technologies Mr. Jyoti Roy, DVP - Equity Strategist, Angel Broking Ltd


I-direct Instinct - Intellect Design Arena

P&G Health - Company Update - ICICI Securities

Relaxo Footwears - Mr. Amarjeet Maurya- AVP - Mid Caps, Angel Broking Ltd

Bata India - Mr. Amarjeet Maurya- AVP - Mid Caps, Angel Broking Ltd

Listing of Happiest Minds Technologies - Angel Broking

Dr. Reddy's Lab - Sep 17, 2020 - Angel Broking

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019